Skip to main content

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 618777. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46511, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/714836/Champions-Oncology-to-Announce-First-Quarter-Financial-Results-on-Thursday-September-8-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.09
-6.02 (-2.87%)
AAPL  267.63
+3.05 (1.15%)
AMD  195.64
-4.51 (-2.25%)
BAC  51.28
-1.78 (-3.35%)
GOOG  312.75
-2.15 (-0.68%)
META  638.88
-16.78 (-2.56%)
MSFT  386.26
-10.97 (-2.76%)
NVDA  190.91
+1.09 (0.58%)
ORCL  140.09
-7.99 (-5.40%)
TSLA  394.58
-17.24 (-4.19%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.